Reuters logo
10 months ago
BRIEF-CMX157 demonstrates 99 pct viral load reduction clinical study versus Viread in Hepatitis B patients
October 13, 2016 / 10:26 AM / 10 months ago

BRIEF-CMX157 demonstrates 99 pct viral load reduction clinical study versus Viread in Hepatitis B patients

Oct 13 (Reuters) - Contravir Pharmaceuticals Inc

* CMX157 demonstrates 99% viral load reduction in ongoing head-to-head phase 2A clinical study versus. Viread in Hepatitis B patients

* Contravir Pharmaceuticals Inc - study achieves proof of concept for CMX157 in HBV patients with favorable therapeutic profile

* Contravir Pharmaceuticals Inc- CMX157 was earlier found to be safe and well tolerated at daily oral doses of up to 100 mg in volunteers Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below